ACADIA's ACP-204 open-label extension study in Lewy body dementia psychosis remains recruitingSep 29Trial updateACADIA Pharmaceuticals Inc.ACP-204
Acadia's remlifanserin narrowly misses primary endpoint in Phase 2 Alzheimer's psychosis studySep 24Clinical readoutACADIA Pharmaceuticals Inc.
Acadia raises 2026 revenue guidance on DAYBUE and NUPLAZID growthAug 4Quarterly updateACADIA Pharmaceuticals Inc.pimavanserin
Sign in